A case series of patients treated with inotuzumab ozogamicin for acute lymphoblastic leukemia relapsed after allogeneic hematopoietic cell transplantation

[1]  H. Kantarjian,et al.  Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22 , 2021, Clinical Cancer Research.

[2]  R. Cassaday,et al.  Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient? , 2020, Current oncology.

[3]  T. Yamauchi,et al.  Clinical Significance of Inotuzumab Ozogamicin in Non-transplant Patients with Relapsed Acute Lymphoblastic Leukemia: A Report of Four Cases , 2020, Internal medicine.

[4]  W. Saber,et al.  Prior Gemtuzumab Ozogamicin Exposure in Adults With Acute Myeloid Leukemia Does Not Increase Hepatic Veno-occlusive Disease Risk After Allogeneic Hematopoietic Cell Transplantation: A CIBMTR Analysis. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  M. Hino,et al.  Inotuzumab ozogamicin versus standard of care in Asian patients with relapsed/refractory acute lymphoblastic leukemia , 2019, International Journal of Hematology.

[6]  S. Kako,et al.  Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome‐positive acute lymphoblastic leukemia , 2019, Cancer science.

[7]  M. Mohty,et al.  Risk Factors for Development of and Progression of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  M. Liedtke,et al.  Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study , 2019, Cancer.

[9]  M. Konopleva,et al.  Chemoimmunotherapy with inotuzumab ozogamicin combined with mini‐hyper‐CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome–negative acute lymphoblastic leukemia in first salvage , 2018, Cancer.

[10]  H. Kantarjian,et al.  Patient‐reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia , 2018, Cancer.

[11]  M. Konopleva,et al.  Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini–Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial , 2017, JAMA oncology.

[12]  H. Kantarjian,et al.  Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. , 2017, The Lancet. Haematology.

[13]  H. Nakajima,et al.  Outcome and prognostic factors among patients who underwent a second transplantation for disease relapse post the first allogeneic cell transplantation , 2017, Leukemia & lymphoma.

[14]  W. Klapper,et al.  Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia , 2017, The New England journal of medicine.

[15]  J. Esteve,et al.  Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome–positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transpl , 2016, Cancer.

[16]  M. Liedtke,et al.  Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. , 2016, The New England journal of medicine.

[17]  M. Abecassis,et al.  Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation , 2016, Bone Marrow Transplantation.

[18]  R. D'Agostino,et al.  Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. , 2016, Blood.

[19]  M. Abecassis,et al.  Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives—a position statement from the European Society for Blood and Marrow Transplantation (EBMT) , 2015, Bone Marrow Transplantation.

[20]  H. Kantarjian,et al.  Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody , 2015, American journal of hematology.

[21]  Pamela A Shaw,et al.  Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.

[22]  T. Clackson,et al.  A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. , 2013, The New England journal of medicine.

[23]  S. Kako,et al.  Outcome after first relapse in adult patients with Philadelphia chromosome‐negative acute lymphoblastic leukaemia , 2013, British journal of haematology.

[24]  K. Kreuzer,et al.  Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. , 2012, Blood.

[25]  M. Labopin,et al.  Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT , 2012, Leukemia.

[26]  H. Fan,et al.  Real-time quantitative reverse transcriptase polymerase chain reaction. , 2010, Methods in molecular biology.

[27]  J. Mestan,et al.  Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. , 2005, Blood.

[28]  P. Richardson,et al.  Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. , 2003, Blood.

[29]  J. Gabert,et al.  Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects , 2003, Leukemia.